Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
428 results about "Tetrahydropyran" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Tetrahydropyran (THP) is the organic compound consisting of a saturated six-membered ring containing five carbon atoms and one oxygen atom. It is named by reference to pyran, which contains two double bonds, and may be produced from it by adding four hydrogens. In 2013, its preferred IUPAC name was established as oxane. The compound is a colourless volatile liquid. Derivatives of tetrahydropyran are, however, more common. 2-Tetrahydropyranyl (THP-) ethers derived from the reaction of alcohols and 3,4-dihydropyran are commonly used as protecting groups in organic synthesis. Furthermore, a tetrahydropyran ring system, i.e., five carbon atoms and an oxygen, is the core of pyranose sugars, such as glucose.
Process for one-pot synthesis of 1,1-diphenyl-1-(3-substituted-cyclopentadienyl)-1-(2,7-di-t-butyl-fluoren-9-yl)methane type ligands
ActiveUS7468452B1Silicon organic compoundsOrganic-compounds/hydrides/coordination-complexes catalystsAnsa-metallocenePhenyl group
The present invention is directed to a method of making a ligand which can be used to form an ansa-metallocene. Further, the present invention is directed to a method of making the ansa-metallocene. In both methods the process steps employed to form the ligand are conducted in the presence of tetrahydrofuran, a substituted tetrahydrofuran, tetrahydropyran, a substituted tetrahydropyran or ethylene glycol dimethyl ether.
Owner:CHEVRON PHILLIPS CHEMICAL CO LP
Salts and crystalline forms of an apoptosis-inducing agent
Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
Owner:ABBVIE INC
Tissue degeneration protection
InactiveUS20100099640A1Improve solubilityHigh dissolution rateBiocideSugar derivativesPharmaceutical medicinePharmacology
The present invention provides isolated or essentially pure diterpenoic tetrahydropyran, such as steviol-19-glucuronide, steviol, stevioside and rebaudioside processes for obtaining the same and methods for obtaining stable pharmaceutically acceptable salts of the same for use of such compounds or compositions in a treatment of cardiovascular disorders or vascular disease or for the manufacture of medicaments to treat a condition of a cardiovascular disorder or vascular disease.
Owner:GEUNS JOANNES +1
Alkenyl compound having a negative delta epsilon value, liquid crystal composition, and liquid crystal display device
InactiveUS20040065866A1Low viscosityImprove solubilityLiquid crystal compositionsSilicon organic compoundsLiquid crystallineDithiane
Owner:JNC CORP
17-hydroxy c27 steroid compound and its synthesis and use
Owner:SHANGHAI INST OF ORGANIC CHEM CHINESE ACAD OF SCI
3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) including any stereochemically isomeric form thereof, or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic glutamate receptors subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and such compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
Owner:ADDEX PHARM SA +1
Photoresist polymeric compound and photoresist resin composition
InactiveUS6692889B1Improve corrosion resistanceSatisfactory transparencyPhotosensitive materialsRadiation applicationsSolubilityHydrogen atom
A polymeric compound of the invention includes at least one monomer unit selected from the following formulae (I), (II), (III) and (IV):(wherein R<1 >is a hydrogen atom or a methyl group, R<2 >and R<3 >are each a hydrogen atom, a hydroxyl group or a -COOR<4 >group, where R<4 >is, e.g., a t-butyl group or a 2-tetrahydropyranyl group; R<5 >and R<6 >are each a hydrogen atom, a hydroxyl group or an oxo group; R<7>, R<8 >and R<9 >are each a hydrogen atom or a methyl group; R<10 >and R<11 >are each a hydrocarbon group having 1 to 8 carbon atoms; R<12>, R<13 >and R<14 >are each a hydrogen atom, a hydroxyl group or a methyl group, where if all of R<12 >to R<14 >are each a hydrogen atom or a hydroxyl group, R<10 >and R<11 >are not coincidentally methyl groups) [wherein, when the compound includes, for example, a monomer unit of Formula (III), the compound further includes at least one monomer unit selected from among, for example, a monomer unit represented by the following Formula (V):(wherein R<15 >and R<16 >are each a hydrogen atom, a hydroxyl group or a carboxyl group; R<17 >is a hydroxyl group, an oxo group or a carboxyl group; and R<1 >has the same meaning as defined above)]. This polymeric compound has high etching resistance, as well as satisfactory transparency, alkali-solubility and adhesion, and is therefore useful as a photoresist resin.
Owner:DAICEL CHEM IND LTD
Nucleotide analogs with six-membered rings
InactiveUS7276592B2Efficient synthesisPromote degradationSugar derivativesAntibioticsCyclohexeneTetrahydropyran
Owner:ROCHE DIAGNOSTICS OPERATIONS INC
Pharmaceutical compositions comprising aryl-substituted acyclic enediyne compounds
A pharmaceutical compositions comprises a compound of formula (I): or a pharmaceutically acceptable salt thereof: wherein R1═R2 ═H; or R1 and R2 together form a moiety represented by the formula R3 represents a substituted or unsubstituted alkyl having 4-30 carbon atoms, or a substituted or unsubstituted aryl group having 3-30 carbon atoms; and R4 represents a substituted or unsubstituted aryl group having 3-30 carbon atoms; with the proviso that R3 is not butyl, pentyl, tetrahydropyranyloxymethyl, tetrahydropyranyloxypropyl or phenyl when R1═R2═H and R4 is o-cyanophenyl,; and with the proviso that R3 is not butyl when R1═R2═H and R4 is phenyl. The pharmaceutical composition may be used to treat a subject afflicted with a tumor / cancer by inhibiting topoisomerase I activities or blocking the S phase or G2 / M phase of the tumor / cancer cells.
Owner:KAOHSIUNG MEDICAL UNIVERSITY
Synthesis method of high-performance multipurpose urethane elastomer
The invention discloses a synthetic method to prepare polyurethane elastic body with hydroxyl-ended oligomer polyol as raw material, which is characterized by the following: reacting hydroxy-terminated liquid rubber or poly-tetrahydropyran ether alcohol with polyisocyanates; getting end isocyanate group pie polymer in fixing reacting time, temperature; giving in A component; compositing chain-extending agent, flux, antiager with gallant; getting curative; giving in B component; hardening A component and B component under indoor temperature proportional mixing; getting high-performance multipurpose polyurethane elastic body; The stretching intensity is: 10.0-47.0Mpa, splitting extensibility>300%, 300% load at certain intensity: 5.0-35.0Mpa.
Owner:BC P INC CHINA NAT PETROLEUM CORP +1
Novel compound and preparation method and use thereof
InactiveCN101891715AEasy to operateMild responseGroup 4/14 element organic compoundsOrganic reductionMedicinal chemistrySilicon based
Owner:SHANGHAI TECHWELL BIOPHARMACEUTICALS CO LTD
Chlorofluorobenzene liquid crystal compound, liquid crystal composition and liquid crystal display device
ActiveUS20080075891A1Liquid crystal compositionsOrganic compound preparationCrystallographyPyridazine
A liquid crystal compound selected from a group of compounds represented by formula (a): wherein Ra and Rb are each independently alkyl having 1 to 10 carbons, alkoxy having 1 to 9 carbons, alkoxyalkyl having 2 to 9 carbons, alkenyl having 2 to 10 carbons, alkenyloxy having 2 to 9 carbons, fluoroalkyl having 1 to 10 carbons or fluoroalkoxy having 1 to 9 carbons; ring A1, ring A2 and ring A3 are each independently trans-1,4-cyclohexylene, trans-1,3-dioxane-2,5-diyl, trans-tetrahydropyran-2,5-diyl, 1,4-phenylene, 2-fluoro-1,4-phenylene, 2,3-difluoro-1,4-phenylene, 2,5-difluoro-1,4-phenylene, 2,6-difluoro-1,4-phenylene, pyridine-2,5-diyl, 6-fluoropyridine-2,5-diyl or pyridazine-2,5-diyl; Z1, Z2 and Z3 are each independently a single bond, —(CH2)2—, —CH═CH—, —C≡C—, —CH2O, —OCH2—, —COO—, —OCO—, —OCF2—, —CF2O—, —CH2CH2OCF2— or —CF2OCH2CH2—; l, m and n are each independently 0, 1 or 2, provided that l+m+n is 0, 1, 2 or 3; one of X1 and X2 is fluorine, and the other is chlorine; Q is and atoms comprising the compound each may be an isotope thereof.
Owner:JNC PETROCHEM +1
Liquid crystal composition and liquid crystal display device
InactiveUS20080303001A1High stability to ultraviolet lightShort response timeLiquid crystal compositionsThin material handlingUltraviolet lightsPhenyl group
The invention is to provide a liquid crystal composition that satisfies at least one characteristic among the characteristics such as a high maximum temperature of a nematic phase, a low minimum temperature of a nematic phase, a small viscosity, a large optical anisotropy, a negatively large dielectric anisotropy, a large specific resistance, a high stability to ultraviolet light, a high stability to heat and so forth. A liquid crystal composition having a negative dielectric anisotropy comprising two components, wherein the first component is at least one compound selected from the group of compounds represented by formula (1-1) and formula (1-2), and the second component is at least one compound selected from the group of compounds represented by formula (2-1) and formula (2-2):wherein R1 and R2 are each independently alkyl having 1 to 12 carbons, alkoxy having from 1 to 12 carbons, alkenyl having 2 to 12 carbons or alkenyl having 2 to 12 carbons, arbitrary hydrogen of which is replaced by fluorine; Z1 is a single bond, ethylene, methyleneoxy or carbonyloxy; ring A and ring B are each independently tetrahydropyran-2,5-diyl, 1,4-cyclohexylene, or 1,4-phenylene, at least one of ring A and ring B is tetrahydropyran-2,5-diyl.
Owner:JNC PETROCHEM CORP +1
Salt form of a human histone methyltransferase EZH2 inhibitor
Owner:EISIA R&D MANAGEMENT CO LTD +1
17 alpha, 22-dicarboxy furo compound and its use
This invention refers to 17alpha ,22 - dihydroxy Furan Steride compounds and its application. The compound' s structure formula is drawing in right graph, wherein the R1, R2 and R3 = H, C1-10 direct chain, cyclane group or alkenyl , triethylsilyl, dimethyl- tert-butylsilyl-biphenyl-tert-butylsilyl, methoxymethyl or tetrahydropyranyl. R4 = H see right formula a, b, C1-10 direct chain, cyclane group, alkenyl or alkynyl , R5 = C1-10 direct chain or cyclane group, R6 = H, C1-10 direct chain or cyclane group or alkenyl, triethylsilyl, dimethyl- tert-butylsilyl, biphenyl-tert-butylsilyl, methoxymethyl, tetrahydropyranyl. The start materials is diosgenin, which is easy available and cheap. Through F-cyclic degrading, the degradation product' s structure is converted into 17alpha,22 - dihydroxy furan steride compound. The compound again with F-cyclic restructure becomes the sapogenin, which is medicinal value. The process thereof is simple, adapted for industrialized production. It's glycoside of medicinal herbs Chonglou (Paris petiolata bak) sapogenin as one active ingredient, whose synthesis is provided herewith is effectively.
Owner:SHANGHAI INST OF ORGANIC CHEMISTRY - CHINESE ACAD OF SCI +1
Calixresorcinarene compounds, photoresist base materials, and compositions thereof
A calixresorcinarene compound shown by the following formula (1), wherein R individually represents a hydrogen atom, a 1-tetrahydropyranyl group, a 1-tetrahydrofuranyl group, or one or more organic groups selected from the group consisting of the organic groups shown by the following formulas, wherein n individually represents an integer of 1 to 50, provided that a compound in which R is selected only from a hydrogen atom, a 1-tetrahydropyranyl group, and a 1-tetrahydrofuranyl group is excluded.
Owner:IDEMITSU KOSAN CO LTD
Aryl-substituted acyclic enediyne compounds
This invention provides aryl-substituted acyclic enediyne compounds of formula (I):or a pharmaceutically acceptable salt or solvate thereof,whereinR1=R2=H; or R1 and R2 together form a moiety represented by the formulaR3 represents a substituted or unsubstituted alkyl having 4-30 carbon atoms, or a substituted or unsubstituted aryl group having 3-30 carbon atoms; andR4 represents a substituted or unsubstituted aryl group having 3-30 carbon atoms;with the proviso that R3 is not butyl, pentyl, tetrahydropyranyloxymethyl, tetrahydropyranyloxypropyl or phenyl when R1=R2=H and R4 is o-cyanophenyl,; and with the proviso that R3 is not butyl when R1=R2=H and R4 is phenyl.The compounds of formula (I) are found to have inhibitory activities against topoisomerase I or act as a S phase or G2 / M phase blocker.
Owner:KAOHSIUNG MEDICAL UNIVERSITY
Bose factor polypeptide anti-wrinkle eye cream and preparation method thereof
PendingCN112402310ARepair damaged barrierIncrease elasticityCosmetic preparationsToilet preparationsIllicium verumOphthalmology
The invention discloses a Bose factor polypeptide anti-wrinkle eye cream and a preparation method thereof. The eye cream provides a conditioner with main active ingredients, and the conditioner comprises tocopheryl acetate, hexapeptide-9, palmitoyl pentapeptide-4, tripeptide-1, palmitoyl palmitoyl tripeptide-5, palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, hydroxypropyl tetrahydropyrantriol (Bose factor), carnosine, glycosphingolipid, illicium verum callus culture filtrate and rosa damascena flower oil. The eye cream can effectively promote the generation of eye skin collagen, increase theelasticity and compactness of the skin, prevent wrinkles from deepening and repair the damaged barrier of the eye skin, and has the effects of wrinkle resistance, whitening and oxidation resistance.
Owner:广州市妆妍生物技术有限公司
Liquid crystal composition and liquid crystal display device
InactiveUS7767279B2High stability to ultraviolet lightShort response timeLiquid crystal compositionsThin material handlingUltraviolet lightsFluorine
The invention is to provide a liquid crystal composition that satisfies at least one characteristic among the characteristics such as a high maximum temperature of a nematic phase, a low minimum temperature of a nematic phase, a small viscosity, a large optical anisotropy, a negatively large dielectric anisotropy, a large specific resistance, a high stability to ultraviolet light, a high stability to heat and so forth. A liquid crystal composition having a negative dielectric anisotropy comprising two components, wherein the first component is at least one compound selected from the group of compounds represented by formula (1-1) and formula (1-2), and the second component is at least one compound selected from the group of compounds represented by formula (2-1) and formula (2-2):wherein R1 and R2 are each independently alkyl having 1 to 12 carbons, alkoxy having from 1 to 12 carbons, alkenyl having 2 to 12 carbons or alkenyl having 2 to 12 carbons, arbitrary hydrogen of which is replaced by fluorine; Z1 is a single bond, ethylene, methyleneoxy or carbonyloxy; ring A and ring B are each independently tetrahydropyran-2,5-diyl, 1,4-cyclohexylene, or 1,4-phenylene, at least one of ring A and ring B is tetrahydropyran-2,5-diyl.
Owner:JNC PETROCHEM CORP +1
Derivatives of 4-(trifluoromethyl)-phenol and 4-(trifluoromethylphenyl)-2-(tetrahydropyranyl) ether and method for producing the same
InactiveUS20040092754A1High yieldLower requirementSilicon organic compoundsOrganic compound preparationEtherElectrophile
The invention relates to a method for producing 2- and 2,5-substituted derivatives of 4-(trifluoromethyl)-phenol and 4-(2-trifluoromethyl)-phenyl)-2-tetrahydropyranyl) ether and to novel derivatives. Said method is characterised in that a compound of formula (2) 4-(trifluoromethylphenyl)-2-(tetrahydropyranyl) ether is reacted with an electrophile E-X or a combination of electrophiles E-X and E-Y in the presence of a base, X and Y having the meanings given in the description.
Owner:BASF AG
Electrolyte solution and use therefor
InactiveUS20110229772A1Increase resistancePrevent and reduce damageOrganic chemistryCell electrodesSupporting electrolyteCyclic ether
The present invention provides an electrolyte solution including: a solvent composed primarily of a BF3-cyclic ether complex; and a supporting electrolyte. For example, preferred is an electrolyte solution in which the cyclic ether is one or two or more selected from optionally substituted tetrahydrofuran and optionally substituted tetrahydropyran.
Owner:TOYOTA JIDOSHA KK +1
Method for preparing intermediate of axitinib and application of intermediate in preparation of axitinib
The invention relates to a method for preparing an intermediate of axitinib and application of the intermediate in preparation of axitinib. The preparation method for the intermediate of axitinib 3-iodine-6-nitro-1-(teralin-2H-pyran-2-base)-1H-indazole comprises the following steps that 6-nitroindazole and 3,4-dihydro-2H-pyran react under the action of catalyst so as to protect perssad tetralin-2H-pyran-2-base at N-H site, and the key intermediate with high yield is obtained through iodination at site 3. The application of the intermediate in preparation of axitinib is as follows: Heck coupled reaction is carried out on the intermediate and 2-vinyl pyridine, then nitro reduction and diazo-reaction for iodination are sequentially carried out, finally, the axitinib is obtained after docking of 2-sulfydryl-N-methyl benzamide and deprotection. The related main initial raw materials are easy to purchase in markets, and the method has high yield and high molecule economic efficiency, is efficient and environment-friendly, and is suitable for industrial mass production.
Owner:湖南欧亚药业有限公司
Synthetic method of hydroxypropyl tetrahydropyrantriol
InactiveCN111559998AAvoid residueQuality assuranceOrganic chemistryBiochemical engineeringCombinatorial chemistry
The invention discloses a synthetic method of hydroxypropyl tetrahydropyrantriol, belonging to the technical field of fine chemicals. Xylose is used as a raw material and is subjected to a two-step reaction to prepare hydroxypropyl tetrahydropyrantriol. The synthetic method is simple in preparation process, preparation yield is high, reagents are cheap and easy to obtain, and good industrial prospects are obtained.
Owner:铭颜生物科技(广州)有限公司
Substituted methylene pyrones derivatives and their preparing process and use
The present invention relates to compound with 6-aryl-3-substituted methylene-pyrone structure, derivative with 6-aryl-3-methyl-4-acryloxy tetrahydro pyrone skeleton, and their preparation process and use. Pharmacological activity test shows that the compound possesses acetylcholinesterase inhibiting activity and is expected to be used as medicine for senile dementia. The compound also shows relatively high activity of inhibiting tumor cells of prostate cancer, oral epithelium cancer, lung cancer and cervical cancer and thus is expected to be used as antitumor medicine.
Owner:浙江海正集团有限公司
Electrolyte solution and use thereof
InactiveCN102150314AOrganic chemistryFinal product manufactureElectrolytic agentSupporting electrolyte
Owner:TOYOTA JIDOSHA KK +1
Chlorofluorobenzene liquid crystal compound, liquid crystal composition and liquid crystal display device
ActiveUS7695777B2Liquid crystal compositionsHalogenated hydrocarbon preparationCrystallographyPyridazine
A liquid crystal compound selected from a group of compounds represented by formula (a):wherein Ra and Rb are each independently alkyl having 1 to 10 carbons, alkoxy having 1 to 9 carbons, alkoxyalkyl having 2 to 9 carbons, alkenyl having 2 to 10 carbons, alkenyloxy having 2 to 9 carbons, fluoroalkyl having 1 to 10 carbons or fluoroalkoxy having 1 to 9 carbons; ring A1, ring A2 and ring A3 are each independently trans-1,4-cyclohexylene, trans-1,3-dioxane-2,5-diyl, trans-tetrahydropyran-2,5-diyl, 1,4-phenylene, 2-fluoro-1,4-phenylene, 2,3-difluoro-1,4-phenylene, 2,5-difluoro-1,4-phenylene, 2,6-difluoro-1,4-phenylene, pyridine-2,5-diyl, 6-fluoropyridine-2,5-diyl or pyridazine-2,5-diyl; Z1, Z2 and Z3 are each independently a single bond, —(CH2)2—, —CH═CH—, —C≡C—, —CH2O, —OCH2—, —COO—, —OCO—, —OCF2—, —CF2O—, —CH2CH2OCF2— or —CF2OCH2CH2—; l, m and n are each independently 0, 1 or 2, provided that l+m+n is 0, 1, 2 or 3; one of X1 and X2 is fluorine, and the other is chlorine; Q isand atoms comprising the compound each may be an isotope thereof.
Owner:JNC PETROCHEM CORP +1
Enantiopure 4-deoxypentenosides, dihydropyrans and tetrahydropyrans and syntheses thereof
Owner:PURDUE RES FOUND INC
Nematic liquid crystal composition
ActiveUS20150184076A1Stable liquid crystal phaseImprove reliabilityLiquid crystal compositionsNon-linear opticsDielectric anisotropyRefractive index
A liquid crystal composition exhibits a positive dielectric anisotropy and sufficiently low viscosity without decreasing or increasing refractive index anisotropy or nematic phase-isotropic liquid phase transition temperature, and does not cause display failures. The liquid crystal composition contains one or more compounds selected from compounds represented by general formula (LC0) and one or more compounds selected from a group of compounds represented by general formula (LC1) to general formula (LC5), in which the liquid crystal composition contains one or more compounds in which at least one of A01, A02, and A11 to A42 in general formulae (LC0) to (LC4) represents a tetrahydropyran-2,5-diyl group.
Owner:DAINIPPON INK & CHEM INC
Salt form of a human histone methyltransferase ezh2 inhibitor
ActiveUS20150065503A1Inhibits histone methyltransferase activityOrganic active ingredientsOrganic chemistry methodsHydrobromideMorpholine
Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
Owner:EISIA R&D MANAGEMENT CO LTD +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com